SCHEMBL5374178

SCHEMBL5374178

Cc1c(O)ccc(C=C2C(=O)Nc3ccc(CCCl)cc32)c1O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 1/20 0.48
TAB1 Q15750 1/20 0.48
LRRK2 Q5S007 4/20 0.45
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CTRC Q99895 1/20 0.41
PDPK1 O15530 4/20 0.41
PLK4 O00444 2/20 0.41
RAF1 P04049 1/20 0.41
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40
PDGFRB P09619 1/20 0.40
PSEN1 P49768 1/20 0.40
PSEN2 P49810 1/20 0.40
APH1B Q8WW43 1/20 0.40
NCSTN Q92542 1/20 0.40
APH1A Q96BI3 1/20 0.40
PSENEN Q9NZ42 1/20 0.40
KDR P35968 1/20 0.40
PLK1 P53350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7137229 0.84 MAP3K7 (0.50) MAP3K7TAB1LRRK2MEN1KMT2A
SCHEMBL5367186 0.82 LRRK2 (0.53) LRRK2EGFRERBB2PDGFRBPSEN1
SCHEMBL5377096 0.81 PLK4 (0.55) LRRK2MEN1KMT2APLK4RAF1
SCHEMBL5367874 0.81 LRRK2 (0.54) LRRK2PDPK1PLK4RAF1EGFR
SCHEMBL5368689 0.81 LRRK2 (0.69) LRRK2MEN1KMT2APDPK1PLK4
SCHEMBL7136887 0.81 MEN1 (0.59) LRRK2MEN1KMT2APDPK1PDGFRB
SCHEMBL5368427 0.81 MDM2 (0.53) LRRK2PDPK1PLK4PDGFRBKDR
SCHEMBL5373291 0.81 MDM2 (0.55) LRRK2PDPK1PLK4PDGFRBKDR
SCHEMBL7136229 0.81 MAP1LC3B (0.57) LRRK2MEN1KMT2APLK4RAF1
SCHEMBL5366299 0.80 LRRK2 (0.53) MAP3K7TAB1LRRK2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MAP3K7 184/4885TAB1 756/4885LRRK2 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.